Clinical trials data
Stroop Color-Word Test in cancer trials: 65 registered studies
Every registered cancer study on ClinicalTrials.gov that names the Stroop Color-Word Test in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered cancer studies name it in an outcome measure
- 65
- Name it in a primary outcome, 51%
- 33 of 65
Tests named in the same studies
- 1
Trail Making Test26 studies, 10 as a primary outcome
- 2
Verbal Learning25 studies, 13 as a primary outcome
- 3
Digit Span Test24 studies, 12 as a primary outcome
- 4
Verbal Fluency24 studies, 10 as a primary outcome
- 5
Continuous Performance Test14 studies, 9 as a primary outcome
- 6
Symbol Coding11 studies, 6 as a primary outcome
- 7
Category Fluency4 studies, 3 as a primary outcome
- 8
Card Sorting Test (Berg)4 studies, 2 as a primary outcome
- 9
Paced Visual Serial Addition Test4 studies, 2 as a primary outcome
- 10
Picture Naming Test4 studies, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 2 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 1 |
| 2010 | 1 | 0 |
| 2011 | 2 | 1 |
| 2012 | 2 | 2 |
| 2013 | 3 | 2 |
| 2014 | 0 | 0 |
| 2015 | 2 | 0 |
| 2016 | 5 | 1 |
| 2017 | 2 | 1 |
| 2018 | 0 | 0 |
| 2019 | 4 | 2 |
| 2020 | 4 | 3 |
| 2021 | 5 | 4 |
| 2022 | 2 | 2 |
| 2023 | 6 | 2 |
| 2024 | 10 | 5 |
| 2025 | 7 | 4 |
| 2026 | 5 | 3 |
Phases and study sizes
By phase
- Phase 24 studies, 1 as a primary outcome
- Phase 31 studies, 0 as a primary outcome
- Phase 41 studies, 0 as a primary outcome
- Not applicable43 studies, 22 as a primary outcome
- Observational16 studies, 10 as a primary outcome
Participants per study
- Not applicable60 median, 25 to 111
- Observational90 median, 55 to 135
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Not applicable | 40 | 60 | 25 to 111 |
| Observational | 15 | 90 | 55 to 135 |
When cancer trials measure it
Latest time point of each outcome
- Within a day7 outcomes, 5 as a primary outcome
- Up to 4 weeks5 outcomes, 3 as a primary outcome
- 1 to 3 months13 outcomes, 7 as a primary outcome
- 3 to 6 months13 outcomes, 4 as a primary outcome
- 6 to 12 months13 outcomes, 6 as a primary outcome
- 1 to 2 years5 outcomes, 3 as a primary outcome
- Over 2 years8 outcomes, 4 as a primary outcome
- No duration given1 outcomes, 1 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
64 of the 65 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting19 studies, 10 as a primary outcome
- Not yet recruiting5 studies, 2 as a primary outcome
- Active, not recruiting3 studies, 0 as a primary outcome
- Completed23 studies, 14 as a primary outcome
- Stopped early9 studies, 3 as a primary outcome
- Status unknown6 studies, 4 as a primary outcome
What they test
- Behavioral24 studies, 14 as a primary outcome
- Drug7 studies, 1 as a primary outcome
- Device12 studies, 6 as a primary outcome
- Procedure5 studies, 1 as a primary outcome
- Diagnostic test1 studies, 0 as a primary outcome
- Biological1 studies, 0 as a primary outcome
- Radiation4 studies, 1 as a primary outcome
- Combination product1 studies, 0 as a primary outcome
- Other21 studies, 11 as a primary outcome
- None given5 studies, 4 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States23 studies, 12 as a primary outcome
- France7 studies, 3 as a primary outcome
- Italy6 studies, 3 as a primary outcome
- Denmark5 studies, 1 as a primary outcome
- Spain4 studies, 3 as a primary outcome
- Australia2 studies, 0 as a primary outcome
- Canada2 studies, 1 as a primary outcome
- Mexico2 studies, 1 as a primary outcome
- Norway2 studies, 0 as a primary outcome
- Slovakia2 studies, 2 as a primary outcome
- United Kingdom2 studies, 0 as a primary outcome
- Austria1 studies, 0 as a primary outcome
22 countries in all. A study with sites in several counts in each; 2 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed cancer studies that name the Stroop Color-Word Test: 9 of 23, 39%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed cancer studies that name the Stroop Color-Word Test | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 2, 9% | 776, 10% |
| Results on ClinicalTrials.gov only | 1, 4% | 1,139, 14% |
| A results paper only | 6, 26% | 1,711, 22% |
| Neither | 14, 61% | 4,327, 54% |
The 65 studies
65 studies match. 33 name the Stroop Color-Word Test in a primary outcome. Median size 67 participants. Median time to the primary outcome: 4 months.
Loading 65 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 that started before 2000 and 1 planned to start after 2026.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 2 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 1 |
| 2010 | 1 | 0 |
| 2011 | 2 | 1 |
| 2012 | 2 | 2 |
| 2013 | 3 | 2 |
| 2014 | 0 | 0 |
| 2015 | 2 | 0 |
| 2016 | 5 | 1 |
| 2017 | 2 | 1 |
| 2018 | 0 | 0 |
| 2019 | 4 | 2 |
| 2020 | 4 | 3 |
| 2021 | 5 | 4 |
| 2022 | 2 | 2 |
| 2023 | 6 | 2 |
| 2024 | 10 | 5 |
| 2025 | 7 | 4 |
| 2026 | 5 | 3 |
Library tests named most
Largest condition groups
Phases
Participants
Lead sponsor: NIH 1, other 64. Interventional 49, observational 16.
As a primary outcomeSecondary or other outcomeThe Stroop Color-Word Test
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07755839 | Start2026 | PhaseNot applicable | ConditionsDepression and bipolar disorder, Cancer, Anxiety, PTSD and OCD | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07716306 | Start2027 | PhaseNot applicable | ConditionsCancer | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07652476 | Start2026 | PhaseObservational | ConditionsCancer | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07479927 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07331077 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants10 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07191119 | Start2026 | PhaseNot applicable | ConditionsCancer, Sleep and sleep disorders | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07173101 | Start2025 | PhasePhase 2 | ConditionsCancer | Participants7 | Lead sponsorOther | StatusStopped early | Library tests named
|
| NCT07147621 | Start2026 | PhaseObservational | ConditionsCancer | Participants120 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06880861 | Start2025 | PhaseObservational | ConditionsCancer | Participants150 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06878469 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants200 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06828003 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants30 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06727370 | Start2024 | PhaseObservational | ConditionsCancer, Lung disease | Participants200 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06618339 | Start2024 | PhaseNot applicable | ConditionsDepression and bipolar disorder, Cancer, Anxiety, PTSD and OCD | Participants19 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06589544 | Start2024 | PhaseNot applicable | ConditionsDepression and bipolar disorder, Cancer | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06553235 | Start2024 | PhaseNot applicable | ConditionsCancer, Sleep and sleep disorders | Participants84 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06468176 | Start2024 | PhaseNot applicable | ConditionsCancer | Participants187 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06419946 | Start2025 | PhasePhase 3 | ConditionsCancer | Participants200 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06312969 | Start2023 | PhaseNot applicable | ConditionsCancer | Participants56 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06281145 | Start2024 | PhaseNot applicable | ConditionsCancer, Sleep and sleep disorders | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06269536 | Start2024 | PhaseNot applicable | ConditionsCancer, Sleep and sleep disorders | Participants50 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06238882 | Start2023 | PhaseNot applicable | ConditionsCancer | Participants74 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06150976 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants7 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06138015 | Start2021 | PhaseNot applicable | ConditionsCancer | Participants80 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06112639 | Start2024 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Multiple sclerosis, Cancer | Participants192 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06073717 | Start2024 | PhaseNot applicable | ConditionsCancer | Participants108 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
Questions, answered from the data
How many cancer trials use the Stroop Color-Word Test?
65 registered cancer studies on ClinicalTrials.gov name it in an outcome measure, 33 of them in a primary outcome: 9% of the condition's 760 studies with a cognitive outcome, against 12% of all of them. It is the 5th most named test in cancer trials.
Which tests do cancer trials use with the Stroop Color-Word Test?
The Trail Making Test (26 studies), Verbal Learning (25 studies) and the Digit Span Test (24 studies).
When do cancer trials measure the Stroop Color-Word Test?
Half of the primary outcomes that name the Stroop Color-Word Test are measured within 4 months of the start, and the middle half from 6 weeks to 12 months. 32 primary outcomes give a duration.
How many completed cancer trials that use the Stroop Color-Word Test have reported results?
9 of the 23 completed studies that name it, 39%, have reported results: 3 posted them on ClinicalTrials.gov, 8 have a results paper linked to the registry record, and 2 did both. The other 14 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
Run the Stroop Color-Word Test in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.